학술논문
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial
Document Type
Academic Journal
Author
Pfeffer, Marc A.; Braunwald, Eugene; Moye, Lemuel A.; Basta, Lofty; Brown, Edward J., Jr.; Cuddy, Thomas E.; Davis, Barry R.; Geltman, Edward M.; Goldman, Steven; Flaker, Greg C.; Klein, Marc; Lamas, Gervasio A.; Packer, Milton; Rouleau, Jacques; Rouleau, Jean L.; Rutherford, John; Wertheimer, John; Hawkins, C. Morton
Source
The New England Journal of Medicine. Sept 3, 1992, Vol. v327 Issue n10, p669, 9 p.
Subject
Language
ISSN
0028-4793
Abstract
Long-term treatment with captopril may prevent cardiovascular events and increase survival in heart attack patients with asymptomatic left ventricular dysfunction. In patients with left ventricular dysfunction, the heart is not capable of pumping enough blood to the body. Of 2,231 heart attack patients with asymptomatic left ventricular dysfunction, 1,115 were treated with captopril and 1,116 received a placebo, an inactive substance, over an average of 42 months. Twenty percent of the patients treated with captopril died, compared with 25% of those who received a placebo. Eighty-four percent of the patients died from a cardiovascular cause. Treatment with captopril decreased the risk of death from all causes by 19%, and the risk of death from cardiovascular causes by 21%. Patients who have survived a heart attack have a higher risk of a heart attack or another cardiovascular event, compared to other individuals.